Celiac and Gluten Sensitivity from Superpower

The national test fee is $79; the New York/New Jersey version is $49. Membership is displayed separately at $199 nationally and $399 for New York/New Jersey. Optional home phlebotomy adds $119 where available. Confirm current billing terms and the full payable total. These fees alone do not establish comparative value.

Exact offer page publishes the measured set: 2 named markers: Total IgA, tTG-IgA. Both regional versions include immunoglobulin A and tissue transglutaminase antibodies for celiac-disease screening.

Results delivered to Superpower dashboard with reference ranges/flagged values; Superpower care team (and AI concierge on most pages) available for interpretation; several pages add an updated Action Plan. Results are typically available within 10 days, with Superpower care-team or personal-provider review. Total IgA and gluten intake can affect antibody interpretation; discuss these with your clinician. The detail of report uncertainty explanations remains unverified.

Performing lab named on the exact offer page (Quest Diagnostics) but the assay method is not stated. Named measurements, professional blood collection and regional laboratories are identified. Assay-specific accuracy, precision and reproducibility remain unverified; general method or laboratory descriptions do not establish those characteristics.

Exact-offer availability list published (40 states, not NY/NJ) plus collection mode (local lab draw / at-home phlebotomist / mail-in kit). Quest Diagnostics processes the national version across 39 named states plus Washington, D.C. New York and New Jersey use BioReference Laboratories. Confirm local collection and home-visit availability. No fasting is required. Discuss gluten intake before testing and the instruction to pause biotin for at least 2 days with your ordering clinician, especially if you already avoid gluten. Do not restart gluten without individualized advice.

Superpower provides platform-wide terms for collecting, using and sharing personal and health information. The handling of this test’s specimens and results across the platform and laboratory, including retention and deletion, remains unverified. Platform terms alone do not resolve every laboratory-specific privacy question.

This is celiac-antibody screening, not a test for non-celiac gluten sensitivity. A positive result does not independently establish a diagnosis; a low total IgA level may affect interpretation and require a different testing approach. Independent clinical utility for this offering remains unassessed.

Regional inclusions, specimen and separate fee components are identified. Assay-specific performance and the final payable total require confirmation.